Prospecto:information for the patient
Jentadueto2,5mg / 850mg film-coated tablets
Jentadueto2,5mg / 1 000mg film-coated tablets
linagliptin/hydrochloride of metformin
Read this prospectus carefully before starting to take this medication, as it contains important information for you.
-Keep this prospectus, as you may need to read it again.
-If you have any doubts, consult your doctor, pharmacist, or nurse.
-This medication has been prescribed only to you, and you should not give it to others who have the same symptoms as you, as it may harm them.
-If you experience adverse effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this prospectus. See section4.
1.What isJentaduetoand for what it is used
2.What you need to know before starting to takeJentadueto
3.How to takeJentadueto
4.Possible adverse effects
5.Storage of Jentadueto
6.Contents of the package and additional information
The name of your tablet isJentadueto. It contains two distinct active ingredients: linagliptina and metformin.
How Jentadueto works
The two active ingredients work together to control blood sugar levels in adult patients with a form of diabetes called “type2 diabetes mellitus”. Along with diet and exercise,this medicationhelps to improve insulin levels and effects after a meal and reduces the amount of sugar produced by your body.
This medicationcan be used alone or with certain diabetes medications such as sulfonylureas, empagliflozin, or insulin.
What is type2 diabetes?
Type2 diabetes is a disease in which your body does not produce enough insulin and the insulin your body produces does not work as well as it should. Your body may also produce too much sugar. When this occurs, sugar (glucose) accumulates in the blood. This can lead to serious medical problems, such as heart diseases, kidney diseases, blindness, and amputations.
Do not take Jentadueto
Do not take Jentadueto if any of the above circumstances apply to you. If you are unsure, consult your doctor or pharmacist before starting to take this medicine.
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to take Jentadueto
If you have symptoms of acute pancreatitis, such as severe and persistent abdominal pain, you should consult your doctor.
If you find blisters on your skin, it could be a sign of a condition called bullous pemphigoid. Your doctor may advise you to stop taking Jentadueto.
If you are unsure whether you are affected by any of the above circumstances, consult your doctor, pharmacist or nurse before starting to take Jentadueto.
Diabetic skin problems are a common complication of diabetes. Follow the skin and foot care recommendations given by your doctor or nurse.
Risk of lactic acidosis
Jentadueto may cause a rare but serious side effect called lactic acidosis, especially if your kidneys are not functioning properly.The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting or alcohol consumption, dehydration (see below), liver problems and any medical condition in which a part of the body has a reduced oxygen supply (such as acute and severe heart disease).
If any of the above applies to you, consult your doctor for further instructions.
Stop taking Jentadueto for a short period of time if you have a condition that may be associated with dehydration (significant loss of body fluids), such as intense vomiting, diarrhea, fever, exposure to heat or if you drink less fluid than normal. Consult your doctor for further instructions.
Stop taking Jentadueto and contact a doctor or the nearest hospital immediately if you experience any of the symptoms that cause lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and should be treated in a hospital.
If you need to undergo major surgery, stop taking Jentadueto while the procedure is being performed and for a period of time afterwards. Your doctor will decide when to stop and when to restart treatment with Jentadueto.
During treatment with Jentadueto, your doctor will check your kidney function at least once a year or more frequently if you are an elderly patient and/or if your kidney function is deteriorating.
Children and adolescents
This medicine is not recommended for children and adolescents under 18 years of age.Jentadueto is not effective in children and adolescents aged 10 to 17 years. The safety and efficacy of this medicine in children under 10 years of age have not been established.
Other medicines and Jentadueto
If you need to be administered an injection of a contrast medium containing iodine, for example, in the context of a radiograph or other imaging examination, stop taking Jentadueto before the injection or at the time of the injection.Your doctor will decide when to stop and when to restart treatment with Jentadueto.
Inform your doctor if you are taking, have taken recently or may need to take any other medicine. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of Jentadueto. It is especially important to mention the following:
Taking Jentadueto with alcohol
Avoid excessive alcohol consumption while taking Jentadueto, as this can increase the risk of lactic acidosis (see section "Warnings and precautions").
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
You should not use Jentadueto if you are pregnant. The safety of this medicine for the fetus has not been established.
Metformin passes into breast milk in small amounts. It is not known whether linagliptin passes into breast milk.Consult your doctor if you wish to breastfeed while taking this medicine.
Driving and operating machinery
The influence of Jentadueto on the ability to drive and operate machinery is negligible or insignificant.
However, taking Jentadueto in combination with sulfonylureas or insulin can cause low blood sugar (hypoglycemia), which can affect your ability to drive and operate machinery or work safely without a secure support.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
How much to take
The amount of Jentadueto you will take varies depending on your situation and the doses of metformin and/or individual linagliptin and metformin tablets you are currently taking. Your doctor will indicate exactly the dose of this medication you should take.
How to take this medication
You should not exceed the recommended maximum daily dose of 5 mg of linagliptin and 2,000 mg of hydrochloride metformin.
Continue taking Jentadueto as prescribed by your doctor to help control your blood sugar level.Your doctor may prescribe this medication along with other oral antidiabetic medications or insulin. Remember to take all your medications as instructed by your doctor for the best results for your health.
During treatment with Jentadueto, continue with your diet and make sure that carbohydrate intake is evenly distributed throughout the day. If you are overweight, continue with your low-calorie diet as instructed.It is unlikely that this medication will only cause an abnormal drop in blood sugar (hypoglycemia). When Jentadueto is used with a medication containing a sulfonylurea or with insulin, a drop in blood sugar may occur and your doctor may reduce the dose of your sulfonylurea or insulin.
If you take more Jentadueto than you should
If you take more Jentadueto tablets than you should, you may experience lactic acidosis. The symptoms of lactic acidosis are non-specific, such as nausea, vomiting, stomach pain with muscle cramps, a general feeling of discomfort with intense fatigue and difficulty breathing.Other symptoms are reduced body temperature and heart rate.If this occurs, you may need immediate hospital treatment, as lactic acidosis can lead to coma. Stop taking this medication immediately and contact a doctor or the nearest hospital immediately (see section 2).Bring the medication packaging with you.
If you forget to take Jentadueto
If you forget to take a dose, take it as soon as you remember.However, if there is little time left for your next dose, do not take the missed dose. Do not take a double dose to compensate for the missed doses. Never take two doses at once (morning or evening).
If you interrupt treatment with Jentadueto
Continue taking Jentadueto until your doctor tells you to stop. This will help you maintain control of your blood sugar.
If you have any other doubts about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines,this medicinecan cause side effects, although not everyone will experience them.
Some symptoms require immediate medical attention
Stop taking Jentadueto andseek medical help immediatelyif you experience the following symptoms oflow blood sugar (hypoglycemia):shaking, sweating, anxiety, blurred vision,tingling in the lips, paleness, mood changes or confusion.Hypoglycemia (frequency: very common[may affect more than 1 in 10people]) is an identified adverse effect for the combination of Jentadueto plus sulfonylurea and for the combination Jentadueto plus insulin.
Jentadueto may cause a rare but serious side effect called lactic acidosis (see section “Warnings and precautions”). If this occurs,stop taking Jentadueto and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to coma.
Some patients have experienced inflammation of the pancreas (pancreatitis;rare frequency, may affect up to 1 in 1,000 people).
STOP taking Jentadueto and consult a doctor immediately if you observe any of the serious side effects below:
Other side effects of Jentadueto include:
Some patients have presented allergic reactions (rare frequency), which can be severe, including wheezing (“whistling” when breathing)and difficulty breathing (bronchial hyperreactivity; infrequent frequency[may affect up to 1 in 100people]). Some patients presented exanthema (skin reaction; infrequent frequency), urticaria (hives; rare frequency) and swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing (angioedema; rare frequency). If you experience any of the signs of illness mentioned above, stop taking Jentadueto and call your doctor quickly. Your doctor may prescribe a medication to treat your allergic reaction and a different medication for your diabetes.
Some patients have experienced the following side effects while taking Jentadueto:
Some patients have experienced the following side effects while taking Jentadueto with insulin:
Side effects when taking metformin alone, which were not described for Jentadueto:
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack, bottle, and box after CAD. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature.
Blister pack: Store in the original packaging to protect it from moisture.
Bottle: Keep the bottle perfectly closed to protect it from moisture.
Do not use this medication if the packaging is damaged or shows signs of tampering.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Jentadueto
-Tablet core: arginine, copovidone, magnesium stearate, cornstarch and anhydrous colloidal silica.
-Film coating: hypromellose, titanium dioxide (E171), talc, propylene glycol.
The Jentadueto 2.5 mg/850 mg film-coated tablets also contain iron oxide red (E172) and iron oxide yellow (E172).
The Jentadueto 2.5 mg/1 000 mg film-coated tablets also contain iron oxide red (E172).
Appearance of the product and contents of the pack
Jentadueto 2.5 mg/850 mg are orange-yellow, oval-shaped, biconvex film-coated tablets with the inscription “D2/850” on one side and the Boehringer Ingelheim logo on the other.
Jentadueto 2.5 mg/1 000 mg are pink, oval-shaped, biconvex film-coated tablets with the inscription “D2/1 000” on one side and the Boehringer Ingelheim logo on the other.
Jentadueto is available in:
Pre-cut single-dose blisters with 10 × 1, 14 × 1, 28 × 1, 30 × 1, 56 × 1, 60 × 1, 84 × 1, 90 × 1, 98 × 1, 100 × 1 and 120 × 1 film-coated tablets.
Multi-pack containers containing 120 × 1 (2 packs of 60 × 1), 180 × 1 (2 packs of 90 × 1), 180 × 1 (3 packs of 60 × 1) and 200 × 1 (2 packs of 100 × 1) film-coated tablets.
Jentadueto is also available in plastic bottles with a screw-cap of plastic and a silica gel desiccant. The bottles contain 14, 60 or 180 film-coated tablets.
Only some pack sizes may be marketed in your country.
Marketing authorisation holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Responsible for manufacturing
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Boehringer Ingelheim Hellas Single Member S.A.
5th km Paiania – Markopoulo
Koropi Attiki, 19441
Greece
Dragenopharm Apotheker Püschl GmbH
Göllstraße 1
84529 Tittmoning
Germany
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:
België/Belgique/Belgien Boehringer Ingelheim SComm Tél/Tel: +32 2 773 33 11 | Lietuva Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel: +370 5 2595942 |
Luxembourg/Luxemburg Boehringer Ingelheim SComm Tél/Tel: +32 2 773 33 11 | |
Ceská republika Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Magyarország Boehringer Ingelheim RCV GmbH & Co KG Magyarországi Fióktelepe Tel: +36 1 299 8900 |
Danmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88 | Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Deutschland Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 900 | Nederland Boehringer IngelheimB.V. Tel: +31 (0) 800 22 55 889 |
Eesti Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal Tel: +372 612 8000 | Norge Boehringer IngelheimDanmark Norwegian branch Tlf: +47 66 76 13 00 |
Ελλ?δα Boehringer IngelheimΕλλ?ς Μονοπρ?σωπη Α.Ε. Tηλ: +30 2 10 89 06 300 | Österreich Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
España Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Polska Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Hrvatska Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | România Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucuresti Tel: +40 21 302 28 00 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana Tel: +386 1 586 40 00 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenskárepublika Boehringer Ingelheim RCV GmbH & Co KG organizacná zložka Tel: +421 2 5810 1211 |
Italia Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102 800 |
Κ?προς Boehringer IngelheimΕλλ?ς Μονοπρ?σωπη Α.Ε. Tηλ: +30 2 10 89 06 300 | Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvija Boehringer Ingelheim RCV GmbH & Co KG Latvijas filiale Tel: +371 67 240 011 | United Kingdom(Northern Ireland) Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Last update of the summary of product characteristics:
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.